Sacral neuromodulation is an approved and validated treatment for overactive bladder syndrome, chronic non-obstructive retention, and chronic pelvic pain. Percutaneous tibial nerve stimulation is a less invasive approach of neuromodulation. We performed a literature research to assess the current evidence available about neuromodulation. Both techniques appear to be effective and safe third-line treatments. The overall success rate ranges from 43% to 85% for sacral neuromodulation and from 40% to 79.5% for percutaneous tibial nerve stimulation. Sacral neuromodulation has a higher incidence of complications in comparison to percutaneous tibial nerve stimulation, due to the more invasive surgical technique and the presence of a permanent implant. The incidence of surgical revision ranges between 9% and 33%. The most frequent complication with sacral neuromodulation is pain at implant site (15%–42%), followed by lead migration (4%–21%), pain at lead site (5.4%–19.1%), leg pain (18%), and infection (5.7%–6.1%). The quality of the studies on sacral neuromodulation and percutaneous tibial nerve stimulation in literature is quite modest, because of the shortage of good randomized clinical trial; most of the studies are prospective observational studies with mid-term follow-up.
SiegelSNoblettKMangelJ, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn2015; 34: 224–230.
4.
SussmanDYehoshuaAKowalskiJ, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract2017; 71(3–4): e12824.
5.
MelzackRWallPD.Pain mechanisms: a new theory. Science1965; 150(3699): 971–979.
6.
GillBCPizarro-BerdichevskyJBhattacharyyaPK, et al. Real-time changes in brain activity during sacral neuromodulation for overactive bladder. J Urol2017; 198(6): 1379–1385.
7.
MaldeSFryCSchurchB, et al. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017. Neurourol Urodyn2018; 37(S4): S108–S116.
8.
StaskinDRPetersKMMacDiarmidS, et al. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep2012; 13(5): 327–334.
9.
SiegelSNoblettKMangelJ, et al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology2016; 94: 57–63.
10.
AmundsenCLRichterHEMenefeeSA, et al. Onabotulinumtoxin A vs sacral neuromodulation on refractory urgency urinary incontinence in women. JAMA2016; 316: 1366.
11.
WeilEHRuiz-CerdáJLEerdmansPH, et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol2000; 37(2): 161–171.
12.
HassounaMMSiegelSWNyeholtAA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol2000; 163(6): 1849–1854.
13.
SchmidtRAJonasUOlesonKA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol1999; 162: 352–357.
14.
NobregaRPSolomonEJenksJ, et al. Predicting a successful outcome in sacral neuromodulation testing: are urodynamic parametersprognostic?Neurourol Urodyn2018; 37(3): 1007–1010.
15.
JadavAMWadhawanHJonesGL, et al. Does sacral nerve stimulation improve global pelvic function in women?Colorectal Dis2013; 15(7): 848–857.
16.
SutherlandSELaversACarlsonA, et al. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn2007; 26(1): 19–28.
17.
PeetersKSahaiADe RidderD, et al. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int2014; 113(5): 789–794.
18.
Van KerrebroeckPEvan VoskuilenACHeesakkersJP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol2007; 178: 2029–2034.
19.
GajewskiJBAl-ZahraniAA.The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int2011; 107(8): 1258–1264.
20.
MyerENBPetrikovetsASlocumPD, et al. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study. Am J Obstet Gynecol2018; 219(1): 78.e1–78.e9.
21.
PetersKMKillingerKAGilleranJP, et al. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn2017; 36(2): 354–359.
22.
BlokBVan KerrebroeckPde WachterS, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn2018; 37(S2): S9–S16.
23.
RoulettePCastel-LacanalESansonS, et al. Sacral neuromodulation and pregnancy: results of a national survey carried out for the neuro-urology committee of the French Association of Urology (AFU). Neurourol Urodyn2018; 37(2): 792–798.
24.
KabaySKabaySCYucelM, et al. Efficiency of posterior tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain: a sham-controlled comparative study. Urol Int2009; 83(1): 33–38.
25.
Gungor UgurlucanFOnalMAslanE, et al. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Invest2013; 75(1): 46–52.
26.
Finazzi-AgròEPettaFSciobicaF, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol2010; 184: 2001–2006.
27.
PetersKMMacDiarmidSAWooldridgeLS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol2009; 182(3): 1055–1061.
28.
PetersKMCarricoDJPerez-MarreroRA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol2010; 183: 1438–1443.
29.
VandoninckVvan BalkenMRFinazzi AgroE, et al. Posterior tibial nerve stimulation in the treatment of idiopathic nonobstructive voiding dysfunction. Urology2003; 61: 567–572.
30.
RostaminiaGChangCPincusJB, et al. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. Epub ahead of print 29 November 2018. DOI: 10.1007/s00192-018-3834-9.
31.
TudorKISethJHLiechtiMD, et al. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Clin Auton Res. Epub ahead of print 3 August 2018. DOI: 10.1007/s10286-018-0553-8.
32.
Vecchioli-ScaldazzaCMorosettiC.Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol2018; 44(1): 102–108.
33.
Del Río-GonzalezSAragonIMCastilloE, et al. Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durability evaluation. Urology2017; 108: 52–58.
